Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 1,174,173 |
|
|||||
| News | - | ||||||
| Day High | 0.39 | Low High |
|||||
| Day Low | 0.2882 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| GRI Bio Inc | GRI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.083 | -20.10% | 0.33 | 19:59:30 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.3891 | 0.2882 | 0.39 | 0.318 | 0.413 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,698 | 1,174,173 | $ 0.3246561 | $ 381,202 | - | 0.2882 - 48.93 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:29 | formt | 1,000 | $ 0.33 | USD |
GRI Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.25M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
GRI Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GRI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.4519 | 0.4798 | 0.2882 | 0.4241862 | 1,359,257 | -0.1219 | -26.97% |
| 1 Month | 0.449 | 0.4798 | 0.2882 | 0.4216639 | 416,004 | -0.119 | -26.50% |
| 3 Months | 0.8287 | 0.915 | 0.2882 | 0.5409084 | 255,205 | -0.4987 | -60.18% |
| 6 Months | 5.5853 | 8.1788 | 0.2882 | 2.19 | 644,511 | -5.26 | -94.09% |
| 1 Year | 46.41 | 48.93 | 0.2882 | 3.38 | 368,880 | -46.08 | -99.29% |
| 3 Years | 92.40 | 93.31 | 0.2882 | 3.93 | 344,256 | -92.07 | -99.64% |
| 5 Years | 92.40 | 93.31 | 0.2882 | 3.93 | 344,256 | -92.07 | -99.64% |
GRI Bio Description
| GRI Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The Company's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company¿s second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need. |
